Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) is a pioneering clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. Agenus is steadfast in its mission to develop innovative immunological therapies aimed at leveraging the body's immune system to combat cancer and other diseases. The company’s diverse product pipeline includes immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc., and vaccine adjuvants through its subsidiary SaponiQx Inc. These products are bolstered by in-house capabilities such as current good manufacturing practice (cGMP) manufacturing and a clinical operations platform.
Agenus has developed several key product candidates, including botensilimab (AGEN1811), a next-generation Fc-engineered CTLA-4 antibody, and balstilimab, a PD-1 antibody. They are currently under investigation for their potential to treat various cancers, particularly difficult-to-treat solid tumors.
The company has achieved significant milestones, including the initiation of various clinical trials for botensilimab and balstilimab. Notably, in April 2024, Agenus announced a one-for-twenty reverse stock split of its issued and outstanding common stock to increase its stock price and meet Nasdaq Capital Market listing requirements. This move is part of a strategic plan to enhance future financing and qualify for inclusion in the Russell Indices.
In its ongoing pursuit of innovative cancer treatments, Agenus recently announced Phase 1 trial results demonstrating encouraging survival rates in patients with metastatic colorectal cancer. The Phase 2 data is expected to be submitted to a major medical conference in the latter half of 2024.
Agenus also engages in strategic partnerships to accelerate its development programs. For instance, a recent agreement with Ligand Pharmaceuticals secures a $100 million capital infusion, specifically aimed at supporting the clinical development and launch readiness of the BOT/BAL combination therapy.
The team at Agenus comprises scientists, researchers, biotechnologists, physicians, and business professionals united by the shared goal of achieving breakthroughs in cancer treatment. This collaborative spirit ensures that Agenus remains at the forefront of transformative cancer therapies, aiming to enhance patient outcomes and extend lives.
For more information, visit www.agenusbio.com or follow @agenus_bio on social media.
Agenus Inc. (NASDAQ: AGEN) announced participation in the Virtual SITC 2020 Immuno-Oncology Event hosted by B. Riley on November 12, 2020. Key executives, including Dr. Steven O'Day and Dr. Jennifer Buell, will lead discussions on Next-Gen Checkpoint Inhibitors and Cell Therapy 2.0. The event includes two panels: The first from 1:00 PM to 2:00 PM ET, and the second from 2:00 PM to 3:00 PM ET. Interested parties can access replays via provided conference IDs.
Agenus focuses on immuno-oncology therapies designed to activate immune responses against cancer.
Agenus Inc. announced a triggered $10M milestone payment from Merck, following the advancement of the ILT4 antibody, MK-4830, into a Phase 2 clinical trial. This novel checkpoint antibody aims to target immune-suppressive cells in tumors. The company is eligible for an additional $85 million in milestones and royalties from sales. Merck is currently evaluating MK-4830 in combination with KEYTRUDA® for treating advanced non-small cell lung cancer. Agenus retains a significant portion of milestones and royalties due to its agreements.
Agenus Inc. (NASDAQ: AGEN) presented seven novel clinical programs at the SITC 2020 Annual Meeting. Key highlights include AGEN1181, showing clinical responses in hard-to-treat tumors and the first report of intratumoral Treg depletion. AGEN1777 offers improved immune performance as an Fc-enhanced TIGIT antibody. AGEN2373 demonstrates clinical benefit without liver toxicity. The proprietary VISION platform predicts treatment responses with high accuracy. Overall, these findings support Agenus's commitment to advancing immuno-oncology therapies.
Agenus Inc. has appointed Dr. Steven O'Day as its new Chief Medical Officer, enhancing its leadership as the company advances its pipeline of immuno-oncology therapies. Dr. O'Day brings over 30 years of experience and has been pivotal in the development of checkpoint antibody treatments. His expertise will support Agenus in rapidly developing clinical trials for their lead candidates. Dr. O'Day is set to present data on AGEN1181, a next-generation anti-CTLA-4 molecule, at an upcoming conference. This strategic appointment aims to accelerate innovative cancer treatments.
Agenus Inc. (NASDAQ: AGEN) has initiated the dosing of its first patient with agenT-797, an allogeneic iNKT cell therapy targeting moderate to severe COVID-19. This innovative therapy aims to eliminate the SARS-CoV-2 virus while curbing excessive inflammation. Additionally, the FDA has approved agenT-797 for cancer treatment, and trials for cancer patients are expected to begin soon. Agenus emphasizes its unique combination of therapies and cost-effectiveness in addressing critical health issues.
Agenus Inc. (NASDAQ: AGEN) provided a corporate update alongside its Q3 2020 financial results. The company initiated its rolling BLA filing for Balstilimab, with FDA review in progress. Recent clinical trials show Balstilimab achieving a 19% response rate in PD-L1 positive tumors and a combination with zalifrelimab yielding 27%. The cash balance rose to $114 million, while Q3 net loss was $52 million, a slight increase from $46 million in Q3 2019. Revenues totaled $14.8 million, down from $19.9 million in the prior year. New data on AGEN1181 will be presented at the upcoming SITC meeting.
Agenus Inc. (NASDAQ: AGEN) will announce its Q3 2020 financial results before the market opens on October 29, 2020. A conference call and webcast will follow at 8:30 AM ET for a discussion of the results and corporate update. Agenus specializes in immuno-oncology with an extensive pipeline including checkpoint antibodies, cell therapies, and vaccines aimed at enhancing immune responses to cancer and infections. The call will be accessible via the company’s website.
Agenus Inc. (NASDAQ: AGEN) announced the acceptance of seven abstracts for the virtual SITC 2020 Annual Meeting, scheduled for November 9-14, 2020. Key presentations include:
- AGEN1181: Demonstrates clinical activity as a standalone or in combination with balstilimab.
- Zalifrelimab: Shows clinical benefit in rare tumors.
- AGEN2373: A CD137 agonist antibody targeting antitumor effects.
- AgenT-797: A novel cell therapy promoting tumor killing.
Updated data will be available on the Agenus website post-conference.
Agenus Inc. (NASDAQ: AGEN) announced the election of Susan Hirsch to its Board of Directors, a significant move as the company prepares for its initial commercial product launches. Garo Armen, Chairman and CEO, praised Hirsch's extensive experience, particularly in identifying high-value companies at critical growth stages. With over 40 years in investment management, including a leadership role at Nuveen, Hirsch's expertise is expected to enhance Agenus' strategic direction. The company is focused on developing therapies that engage the immune system to combat cancer.
Agenus Inc. (NASDAQ: AGEN) announced the initiation of the rolling submission of its Biologics License Application (BLA) for balstilimab, an anti-PD-1 antibody, to the FDA for treating recurrent/metastatic cervical cancer. Results from a significant phase 2 trial indicated response rates of 19% in PD-L1 positive patients and 14% overall. The rolling BLA submission allows for concurrent FDA review of each section as it is completed. The American Cancer Society reported around 14,000 new cervical cancer cases expected this year, highlighting the need for new therapies.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
What does Agenus Inc. specialize in?
Where is Agenus Inc. headquartered?
What are the key products of Agenus Inc.?
What recent strategic financial move did Agenus make?
What significant agreement did Agenus secure recently?
What are some recent clinical trial achievements of Agenus?
What is the focus of Agenus' product candidates?
Who are part of the Agenus team?
How does Agenus support its product development?
Where can investors find more information about Agenus?
